Scaffold and edge vascular response following implantation of everolimus-eluting bioresorbable vascular scaffold: a 3-year serial optical coherence tomography study.

OBJECTIVES This study sought to investigate the in-scaffold vascular response (SVR) and edge vascular response (EVR) after implantation of an everolimus-eluting bioresorbable scaffold (BRS) using serial optical coherence tomography (OCT) imaging. BACKGROUND Although studies using intravascular ultrasound have evaluated the EVR in metal stents and BRSs, there is a lack of OCT-based SVR and EVR assessment after BRS implantation. METHODS In the ABSORB Cohort B (ABSORB Clinical Investigation, Cohort B) study, 23 patients (23 lesions) in Cohort B1 and 17 patients (18 lesions) in Cohort B2 underwent truly serial OCT examinations at 3 different time points (Cohort B1: post-procedure, 6 months, and 2 years; B2: post-procedure, 1 year, and 3 years) after implantation of an 18-mm scaffold. A frame-by-frame OCT analysis was performed at the 5-mm proximal, 5-mm distal edge, and 2-mm in-scaffold margins, whereas the middle 14-mm in-scaffold segment was analyzed at 1-mm intervals. RESULTS The in-scaffold mean luminal area significantly decreased from baseline to 6 months or 1 year (7.22 ± 1.24 mm(2) vs. 6.05 ± 1.38 mm(2) and 7.64 ± 1.19 mm(2) vs. 5.72 ± 0.89 mm(2), respectively; both p < 0.01), but remained unchanged from then onward. In Cohort B1, a significant increase in mean luminal area of the distal edge was observed (5.42 ± 1.81 mm(2) vs. 5.58 ± 1.53 mm(2); p < 0.01), whereas the mean luminal area of the proximal edge remained unchanged at 6 months. In Cohort B2, the mean luminal areas of the proximal and distal edges were significantly smaller than post-procedure measurements at 3 years. The mean luminal area loss at both edges was significantly less than the mean luminal area loss of the in-scaffold segment at both 6-month and 2-year follow-up in Cohort B1 or at 1 year and 3 years in Cohort B2. CONCLUSIONS This OCT-based serial EVR and SVR evaluation of the Absorb Bioresorbable Vascular Scaffold (Abbott Vascular, Santa Clara, California) showed less luminal loss at the edges than luminal loss within the scaffold. The luminal reduction of both edges is not a nosologic entity, but an EVR in continuity with the SVR, extending from the in-scaffold margin to both edges. (ABSORB Clinical Investigation, Cohort B [ABSORB B]; NCT00856856).

[1]  P. Serruys,et al.  I like the candy, I hate the wrapper: the (32)P radioactive stent. , 2000, Circulation.

[2]  G. Mintz,et al.  Serial intravascular ultrasound analysis of peri-stent remodeling and proximal and distal edge effects after sirolimus-eluting or paclitaxel-eluting stent implantation in patients with diabetes mellitus. , 2009, The American journal of cardiology.

[3]  R. Whitbourn,et al.  Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial. , 2012, JACC. Cardiovascular interventions.

[4]  N. Weissman,et al.  Contemporary Reviews in Interventional Cardiology Edge Effect From Drug-Eluting Stents as Assessed With Serial Intravascular Ultrasound A Systematic Review , 2012 .

[5]  P. Serruys,et al.  Early (before 6 months), late (6-12 months) and very late (after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[6]  J. Moses,et al.  Quantitative Assessment of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Native Coronary Arteries , 2004, Circulation.

[7]  P. Fitzgerald,et al.  Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). , 2007, The American journal of cardiology.

[8]  P. Serruys,et al.  Coronary stents: historical development, current status and future directions. , 2013, British medical bulletin.

[9]  R. Whitbourn,et al.  Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[10]  Bernard Chevalier,et al.  First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study , 2012, Circulation. Cardiovascular interventions.

[11]  B. Gersh.  Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial , 2009 .

[12]  C J Slager,et al.  ECG-gated three-dimensional intravascular ultrasound: feasibility and reproducibility of the automated analysis of coronary lumen and atherosclerotic plaque dimensions in humans. , 1997, Circulation.

[13]  Edge Restenosis After Implantation of High Activity 32P Radioactive β-Emitting Stents , 2000 .

[14]  R Waksman,et al.  Endovascular beta-radiation to reduce restenosis after coronary balloon angioplasty: results of the beta energy restenosis trial (BERT). , 1998, Circulation.

[15]  P. Fitzgerald,et al.  Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. , 2009, JACC. Cardiovascular interventions.

[16]  F. Fernández‐Avilés,et al.  Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. , 2006, Journal of the American College of Cardiology.

[17]  G. Stone,et al.  Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials. , 2007, European heart journal.

[18]  P. Serruys,et al.  Edge vascular response after percutaneous coronary intervention: an intracoronary ultrasound and optical coherence tomography appraisal: from radioactive platforms to first- and second-generation drug-eluting stents and bioresorbable scaffolds. , 2013, JACC. Cardiovascular interventions.

[19]  N. Weissman,et al.  Extent and distribution of in-stent intimal hyperplasia and edge effect in a non-radiation stent population. , 2001, The American journal of cardiology.

[20]  P. Serruys,et al.  The edge vascular response following implantation of a fully bioresorbable device: 'a miss always counts'. , 2012, International journal of cardiology.

[21]  V. Bhargava,et al.  Axial movement of the intravascular ultrasound probe during the cardiac cycle: implications for three-dimensional reconstruction and measurements of coronary dimensions. , 1999, American heart journal.

[22]  Akiko Maehara,et al.  Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. , 2012, Journal of the American College of Cardiology.

[23]  C von Birgelen,et al.  ECG-gated versus nongated three-dimensional intracoronary ultrasound analysis: implications for volumetric measurements. , 1998, Catheterization and cardiovascular diagnosis.

[24]  S. Parikh,et al.  Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents. , 2001, Circulation.

[25]  Bernard Chevalier,et al.  Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. , 2011, Journal of the American College of Cardiology.

[26]  P. Serruys,et al.  Intimal Flaps Detected by Optical Frequency Domain Imaging in the Proximal Segments of Native Coronary Arteries. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[27]  “Edge Effect” of 32P Radioactive Stents Is Caused by the Combination of Chronic Stent Injury and Radioactive Dose Falloff , 2001, Circulation.

[28]  Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. , 2004, Journal of the American College of Cardiology.

[29]  R. Whitbourn,et al.  Vascular Responses at Proximal and Distal Edges of Paclitaxel-Eluting Stents: Serial Intravascular Ultrasound Analysis From the TAXUS II Trial , 2004, Circulation.

[30]  Volker Klauss,et al.  Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. , 2010, The New England journal of medicine.

[31]  R Waksman,et al.  Long-term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans. , 1997, Circulation.

[32]  P. Serruys,et al.  In vivo three dimensional optical coherence tomography. A novel imaging modality to visualize the edge vascular response. , 2013, International journal of cardiology.

[33]  D. Schulz,et al.  Late Positive Remodeling and Late Lumen Gain Contribute to Vascular Restoration by a Non-Drug Eluting Bioresorbable Scaffold: A Four-Year Intravascular Ultrasound Study in Normal Porcine Coronary Arteries , 2012, Circulation. Cardiovascular interventions.

[34]  P. Fitzgerald,et al.  SPIRIT III JAPAN versus SPIRIT III USA: a comparative intravascular ultrasound analysis of the everolimus-eluting stent. , 2010, The American journal of cardiology.